Skip to main content Back to Top
Advertisement

10/8/2024

Dulaglutide Injection

Reason for the Shortage

    • Lilly has Trulicity available.

Available Products

    • Trulicity subcutaneous solution for injection, Lilly USA, LLC, 0.75 mg/0.5 mL, pen injector, 4 count, NDC 00002-1433-80
    • Trulicity subcutaneous solution for injection, Lilly USA, LLC, 1.5 mg/0.5 mL, pen injector, 4 count, NDC 00002-1434-80
    • Trulicity subcutaneous solution for injection, Lilly USA, LLC, 3 mg/0.5 mL, pen injector, 4 count, NDC 00002-2236-80
    • Trulicity subcutaneous solution for injection, Lilly USA, LLC, 4.5 mg/0.5 mL, pen injector, 4 count, NDC 00002-3182-80

Estimated Resupply Dates

    • While doses are available, some people still may experience difficulties getting their medication from their pharmacy. This can vary by location based upon supply chain dynamics that are not controlled by Lilly.

Implications for Patient Care

    • Dulaglutide is a GLP-1 receptor agonist that increases post-prandial insulin secretion, reduces glucagon secretion, and slows gastric emptying.[1]
    • Dulaglutide is combined with diet and exercise to improve glycemic control in patients aged 10 and older with type 2 diabetes mellitus.[1]

Safety

    • Lily warned that counterfeiters and compounding pharmacies are dispensing products that are not FDA-approved. The FDA or any global regulatory agency has not reviewed these products for safety, quality, or efficacy. These products may expose patients to serious risks. Lily encourages patients and providers to report suspected counterfeit products to the Lilly Answers Center (TLAC) at 1-800-LillyRx (1-800-545-5979).[2]

Alternative Agents & Management

    • The American Diabetes Association (ADA) describes GLP-1 therapy in adults with type 2 diabetes in section 9 of the standards of care in diabetes.[3]
    • The ADA lists tirzepatide, semaglutide, and high-dose dulaglutide as very effective GLP agents in glucose-lowering.[3]
    • The ADA lists semaglutide and tirzepatide as very effective GLP agents for weight loss in patients with type 2 diabetes.[3]
    • Alternative agents that can have moderate effects on glucose-lowering and aid in weight loss are dulaglutide and liraglutide.[3]

References

    1. Trulicity (dulaglutide) injection, solution. Package insert. Lilly; 2024. Accessed August 8, 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309#section-11.1
    2. Lilly Medicine Supply Information | Lilly Supply Info. Accessed August 9, 2024. https://supply.lilly.com/supply.lilly.com
    3. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes2024. Diabetes Care. 2023;47(Supplement_1):S158-S178. doi:10.2337/dc24-S009

Updated

Updated October 8, 2024 by Michelle Wheeler, PharmD, Drug Information Specialist. Created August 19, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.

ADVERTISEMENT